CELLSOURCE CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,230 JPY | -4.58% |
|
+0.90% | -3.67% |
| 2023 | Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. | CI |
| 2023 | MEDERI Inc. announced that it has received funding from CellSource Co., Ltd. | CI |
| Sales 2024 * | 4.65B 29.23M 2.31B | Sales 2025 * | 5.13B 32.29M 2.55B | Capitalization | 25.53B 161M 12.69B |
|---|---|---|---|---|---|
| Net income 2024 * | 562M 3.54M 279M | Net income 2025 * | 676M 4.25M 336M | EV / Sales 2024 * | 5.5 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.97 x |
| P/E ratio 2024 * |
45.4
x | P/E ratio 2025 * |
37.7
x | Employees | 151 |
| Yield 2024 * |
0.31% | Yield 2025 * |
0.36% | Free-Float | 46.47% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.42% | ||
| 1 week | +0.90% | ||
| Current month | -3.37% | ||
| 1 month | -9.41% | ||
| 3 months | -11.30% | ||
| 6 months | -11.24% | ||
| Current year | -3.67% |
1 week
1 230.00
1 357.00
1 month
1 129.001 380.00
Current year
1 129.001 650.00
1 year
1 129.003 010.00
3 years
1 129.008 160.00
5 years
611.118 160.00
10 years
611.118 160.00
| Managers | Title | Age | Since |
|---|---|---|---|
Masato Tsumamoto
FOU | Founder | 41 | 29/11/15 |
Takashi Sawada
CEO | Chief Executive Officer | 66 | 26/01/22 |
Takeshi Amemiya
BRD | Director/Board Member | 61 | 31/05/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Sawada
CEO | Chief Executive Officer | 66 | 26/01/22 |
Norio Murakami
BRD | Director/Board Member | 77 | 30/09/17 |
Takeshi Amemiya
BRD | Director/Board Member | 61 | 31/05/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.09% | 24 M€ | -16.43% | ||
| 0.28% | 19 M€ | +1.80% | - | |
| 0.02% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/24 | 1,230 | -4.58% | 124 800 |
| 20/06/24 | 1,289 | -0.85% | 84,800 |
| 19/06/24 | 1,300 | -1.81% | 114,900 |
| 18/06/24 | 1,324 | -1.56% | 199,800 |
| 17/06/24 | 1,345 | +10.16% | 345,600 |
Delayed Quote Japan Exchange, June 21, 2024 at 06:29 am
More quotes
CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
Calendar
10/09/2024
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.67% | 161M | |
| -15.40% | 8.55B | |
| +64.74% | 4.23B | |
| +4.65% | 2.68B | |
| -2.80% | 2.61B | |
| -54.53% | 1.82B | |
| -19.59% | 1.66B | |
| -21.51% | 1.42B | |
| +15.98% | 1.19B | |
| -48.13% | 1.05B |
- Stock Market
- Equities
- 4880 Stock
